Ardelyx, Inc. (ARDX)
$3.28+0.31%Close
SELLBEAR · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $810M
- Beta
- 0.68
- P/E (TTM)
- -14.67
- Short % float
- 11.67%
- Days to cover
- 6.6
- SI change
- +8.1%
- 1W
- -1.80%
- 1M
- -9.39%
- vs SPY 1W
- -2.96%
- vs SPY 1M
- -12.38%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$8.1BCRISISQ 10$92.72+7.25%
- PHVSSELLPharvaris N.V.$2.1BCRISISQ 15$30.49-0.06%
- BCRXSELLBioCryst Pharmaceuticals, Inc.$2.1BRECOVERYQ 6$8.10+3.14%
- TRVISELLTrevi Therapeutics, Inc.$1.9BCRISISQ 19$13.72+2.81%
- ZYMESELLZymeworks Inc.$1.9BBEARQ 12$26.21+2.10%
- NTLABUYIntellia Therapeutics, Inc.$1.8BRECOVERYQ 4$12.75+3.73%
- STOKSELLStoke Therapeutics, Inc.$1.6BCRISISQ 11$25.32+3.30%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$26.43+4.75%
- WVESELLWave Life Sciences Ltd.$739MCRISISQ 7$3.75-0.29%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ARDX?
- LOPJLB’s latest quantitative signal on Ardelyx, Inc. (ARDX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ARDX in?
- Ardelyx, Inc. (ARDX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Ardelyx, Inc. (ARDX) do?
- Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed P…